{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-22-005825","form_type":"8-K","ticker":"STRO","cik":"0001382101","company_name":"SUTRO BIOPHARMA, INC.","filed_at":"2022-04-20T23:59:59+00:00","discovered_at":"2026-05-14T18:04:00.423322+00:00","generated_at":"2026-06-26T06:07:19.470839+00:00","sec_items":["1.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Sutro Biopharma amends Tasly license for STRO-002; gets $25M initial, up to $350M in milestones","bullets":["Amendment to Tasly license for STRO-002 in Greater China (China, HK, Macau, Taiwan).","Initial payment revised to $25M; $15M escrow in Q2 2022 payable on regulatory milestones.","Additional potential milestone payments up to $350M for development, regulatory, commercialization.","Tasly retains exclusive rights to develop and commercialize STRO-002 in the region.","Amendment effective April 18, 2022; full terms to be filed in Q2 2022 10-Q."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-22-005825","json":"https://secwatch.observer/filing/0000950170-22-005825.json","markdown":"https://secwatch.observer/filing/0000950170-22-005825.md","text":"https://secwatch.observer/filing/0000950170-22-005825.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1382101/000095017022005825/0000950170-22-005825-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1382101/000095017022005825/stro-20220418.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-26T06:07:19.470839+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}